References
- Krein PM, Sabatini PJB, Tinmouth W, et al. Localization of insulin-like growth factor-I in lung tissues of patients with fibroproliferative acute respiratory distress syndrome. Am J Respir Crit Care Med. 2003;167(1):83–90.
- -Li G, Li J, Zhou Q, et al. Growth hormone releasing peptide-2, a ghrelin agonist, attenuates lipopolysaccharide-induced acute lung injury in rats. Tohoku J Exp Med. 2010;222(1):7–13.
- -Müller C, Wallaschofski H, Brabant G, et al. The association between IGF-I/IGFBP-3 and subclinical end points: epidemiology faces the limits. J Clin Endocrinol Metab. 2014;99(8):2804–2812.
- Soliman AR, Soliman MA, Sadek KM. Growth hormone has protective effects against cardiac changes in elderly renal transplant recipients. Saudi J Kidney Dis Transpl. 2019;30(1):62–67.
- Andonegui G, Krein PM, Mowat C, et al. Enhanced production of IGF-I in the lungs of fibro proliferative ARDS patients. Physiol Rep. 2014;2(11):e12197.
- Ahasic AM, Tejera P, Wei Y, et al. Predictors of circulating insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 in critical illness. Crit Care Med. 2015;43(12):2651–2659.
- Ahasic AM, Zhai R, Su L, et al. IGF1 and IGFBP3 in acute respiratory distress syndrome. Eur J Endocrinol. 2012;166(1):121–129.
- Chen C, Shi L, Li Y, et al. Disease-specific dynamic biomarkers selected by integrating inflammatory mediators with clinical informatics in ARDS patients with severe pneumonia. Cell Biol Toxicol. 2016;32(3):169–184.